INCB 01158-101:Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Start Date:
February 17, 2019
IRB Number:
https://clinicaltrials.gov/ct2/results?id=NCT02903914
Condition/Disease:
Cancer - Gastric,
Cancer - Colorectal,
Cancer - Bladder,
Cancer - Head and Neck,
Cancer - Lung,
Solid Tumors
Principal Investigator: Ding Wang, MD
Purpose of Research:
Cancer, Gastric Cancer, Gastro Cancer, Phase I, Phase 1, Phase 2, Phase II, Solid Tumors, Head and Neck Cancer, Lung Cancer, Bladder Cancer, Metastatic Cancer, Colorectal Cancer, Advanced, Renal Cell, Renal Cell Carcinoma
Status:
Open
